#United States #Elanco Animal Health #Indianapolis #Zenrelia #Credelio Quattro

Elanco Animal Health Reports First Quarter 2026 Results

Elanco Animal Health Incorporated (NYSE: ELAN) has unveiled its financial results for the first quarter of 2026, highlighting a notable revenue increase to $1,371 million, marking a 15% year-over-year growth. The company attributes this success to its commitment to innovative solutions and a diverse product portfolio, demonstrating significant momentum in the animal health sector.

Financial Highlights

The key financial metrics for Q1 2026 are impressive:

• - Reported Net Income: $57 million
• - Adjusted Net Income: $204 million
• - Adjusted EBITDA: $334 million with a margin of 24.5%
• - Reported EPS: $0.11; Adjusted EPS: $0.40

Elanco’s organic constant currency revenue growth stands at 10%, showcasing the effectiveness of its product line and strategic market positioning.

Optimistic Outlook

With a positive outlook for the year, Elanco has raised its full-year revenue guidance to between $5,010 million and $5,085 million. This represents an anticipated organic constant currency growth of 5% to 7%. The adjusted EBITDA expectation has also increased to between $975 million and $1,005 million compared to the previous year, indicating a year-over-year increase of 10% at midpoint. Jeff Simmons, President and CEO of Elanco, stated, “Our strong first quarter results demonstrate the significant momentum of our innovation-led strategy.”

Notable Innovations Driving Growth

A significant driver of this growth is Elanco's innovative products, including:
1. Zenrelia™: Achieving blockbuster status with over 2 million dogs treated and increased market share across multiple regions, especially in the U.S. and Brazil.
2. Credelio Quattro™: Not only gaining traction in U.S. veterinary clinics but also being launched in Australia and approved in Canada. The product's accelerated dollar share gains contribute to its expanding reputation.

This focus on innovation positions Elanco to capture substantial market share and enhance the welfare of animals, aligning with the company’s mission of improving animal health and wellness.

Strategic Initiatives and New Partnerships

Elanco's operational strategies continue to yield results as the company enhances its market penetration. The addition of new retail partnerships, such as with Costco and Dollar General for its parasiticides, demonstrates the company's commitment to expanding its availability and accessibility to pet owners. Furthermore, the launch of the Advantage® Collar for Dogs, offering four-month protection against fleas and ticks, adds to its robust product lineup.

Elanco is also working on expanding its influence in the farm animal sector, showcasing a growth trajectory across all species, notably poultry and ruminants. The company’s strategic efforts are reflected in a strong first-quarter performance, with farm animal segment revenues climbing 18% from the prior year.

Financial Position and Future Guidance

The adjusted net leverage ratio stands at 3.5x adjusted EBITDA, indicating improved financial strength and a solid foundation for future growth. Elanco’s management continuously underscores a disciplined financial approach while embracing innovative strategies to develop new products. The company’s CFO, Bob VanHimbergen, emphasized the focus on balancing ambitious growth with prudent financial management, ensuring stability in a changing macro environment.

For Q2 2026, Elanco anticipates revenue of between $1,300 million and $1,325 million and adjusted EPS ranging from $0.25 to $0.28, indicating consistent growth momentum as the year progresses. This robust performance is expected to drive shareholder value significantly, reflecting the organization’s strategic foresight and adaptable market strategies.

As Elanco continues to innovate and expand, the company remains dedicated to its vision of providing meaningful solutions for animal health, thereby fostering stronger connections between farmers, pet owners, and their animals.